Retinal Therapy Guided by 3D OCT Image Analysis

Age-Related Macular Degeneration Clinical Trial

Official title:

Retinal Therapy Guided by 3D OCT Image Analysis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02308215
• Other study ID #: 201003712
• Secondary ID: 1R01EY019112-01A
• Status: Completed
• Start date: July 2010
• Est. completion date: July 5, 2018

Study information

• Verified date: August 2019
• Source: University of Iowa
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The main purpose is to find a better way to predict the timing of treatments given to patients with Wet Age-related macular degeneration using image analysis.

Description:

The study focuses on making better use of advanced three-dimensional imaging and analysis to allow physicians to know when a treatment is being effective and thus not overuse it. The study will examine how 3-D optical coherence tomography and related image analysis can be used to assess changes in the macula and retina of patients' eyes. These changes can reveal how well a person is responding to anti-VEGF treatment and thus help doctors provide proper treatment timing and care.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 77
• Est. completion date: July 5, 2018
• Est. primary completion date: July 5, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 45 Years to 120 Years

Eligibility

Inclusion Criteria:

• fundoscopically confirmed AMD and patient eligible for treatment with anti-VEGF

Exclusion Criteria:

• Patients with a CNV due to other causes (OHS, trauma)

• eyes that have been previously treated for CNV

Related Conditions & MeSH terms

• Age-Related Macular Degeneration
• Choroidal Neovascularization
• Macular Degeneration
• Neovascularization, Pathologic

Locations

Country	Name	City	State
United States	University of Iowa Hospitals Dept of Ophthalmology	Iowa City	Iowa

Sponsors (2)

Lead Sponsor	Collaborator
Michael Abramoff	National Eye Institute (NEI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Measure central retinal layer thickness in µms.		one year
Primary	Measure amount of fluid in the retina in µms.		one year